Novavax, Inc [NVAX] stock prices are up 4.81% to $6.54 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVAX shares have gain 2.03% over the last week, with a monthly amount drifted -21.58%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novavax, Inc [NASDAQ: NVAX] stock has seen the most recent analyst activity on February 28, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $19. Previously, JP Morgan downgraded its rating to Underweight on July 30, 2024, and kept the price target unchanged to $8. On May 10, 2024, upgrade upgraded it’s rating to Neutral. BofA Securities upgraded its rating to a Neutral and increased its price target to $12 on May 10, 2024. B. Riley Securities upgraded its rating to a Buy but $15 remained the price target by the analyst firm on August 09, 2023. TD Cowen downgraded its rating to Market Perform for this stock on April 20, 2023, and downed its price target to $10. In a note dated March 01, 2023, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $29 to $10.
The stock price of Novavax, Inc [NVAX] has been fluctuating between $3.81 and $23.86 over the past year. Currently, Wall Street analysts expect the stock to reach $20.33 within the next 12 months. Novavax, Inc [NASDAQ: NVAX] shares were valued at $6.54 at the most recent close of the market. An investor can expect a potential return of 210.86% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
The Novavax, Inc [NASDAQ:NVAX] reported sales of 682.16M for trailing twelve months, representing a drop of -69.69%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.26%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is 0.31 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.01 points at the first support level, and at 5.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.85, and for the 2nd resistance point, it is at 7.15.
Ratios To Look Out For
It’s worth pointing out that Novavax, Inc [NASDAQ:NVAX]’s Current Ratio is 0.98. In addition, the Quick Ratio stands at 0.97 and the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 1.54.
Transactions by insiders
Recent insider trading involved King Rachel K., Director, that happened on Dec 13 ’24 when 4150.0 shares were sold. Director, YOUNG JAMES F completed a deal on Dec 31 ’24 to sell 5400.0 shares. Meanwhile, Director YOUNG JAMES F sold 4600.0 shares on Dec 24 ’24.
